Increase of efficacy of thrombolytic therapy in acute myocardial infarction by improvement of the characteristics of new fibrinolytic agents;Effizienzsteigerung der thrombolysetherapie des akuten myokardinfarktes durch verbesserte eigenschaften neuer thrombolytika

Wiener Klinische Wochenschrift

Volumn 112, Issue 17, 2000, Pages 742-748

  Huber, K ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Clot selectivity; Efficacy of thrombolysis; PAI resistance; t PA mutants

Indexed keywords

ALTEPLASE; ANISTREPLASE; FIBRINOLYTIC AGENT; LANOTEPLASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROUROKINASE; RETEPLASE; STAPHYLOKINASE; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; TISSUE PLASMINOGEN ACTIVATOR DERIVATIVE; UROKINASE;

ACUTE HEART INFARCTION; BLOOD CLOT LYSIS; CORONARY REPERFUSION; DRUG EFFICACY; DRUG METABOLISM; DRUG SELECTIVITY; HUMAN; PLASMINOGEN ACTIVATION; REVIEW; SIDE EFFECT;

COMPARATIVE STUDY; ENGLISH ABSTRACT; FIBRINOLYTIC AGENTS; FORECASTING; HUMAN; MYOCARDIAL INFARCTION; PLASMINOGEN ACTIVATORS; RECOMBINANT PROTEINS; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0034665158     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. An international randomized trial comparing thrombolytic strategies for acute myocardial infarction
2. One-year results from the global utilization of streptokinaase and TPA for occluded coronary arteries (GUSTO-I) trial
3. Myokardinfarkt und Thrombolyse
4. The wave front phenomenon of ischemic cell death: I. Myocardial infarct size vs duration of coronary occlusion in dogs
5. Time as an adjunctive agent to thrombolytic therapy
6. Extended mortality benefit of early postinfarction reperfusion
7. Thrombolytic therapy in acute myocardial infarction
8. Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction
9. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after myocardial infarction
10. Trickle down thrombolysis
11. Sixty-minute alteplase protocoll: A new accelerated recombinant tissue-type plasminogen activator regimen for thrombolysis in acute myocardial infarction
12. Abciximab facilitates the rate and extent of thrombolysis: Results of the thrombolysis in myocardial infarction (TIMI) 14 trial
13. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled dose-ranging trial
14. Paradoxical attenuation of fibrinolysis attributable to 'plasminogen steal' and its implication for coronary thrombolysis
15. Die koronare Reokklusion - Ein ungelostes Problem der Thrombolysetherapie des akuten Herzinfarktes
16. PAI-1 resistance: A potential benefit for new fibrinolytic agents
17. Correlation of baseline plasminogen activator inhibitor activity with patency of the infarct artery after thrombolytic therapy in acute myocardial infarction
18. Lysis of platelet-rich thrombi: The role of PAI-1
19. The role of type-1 plasminogen activator inhibitor in failure of thrombolytic therapy with recombinant tissue plasminogen activator
20. Pretreatment plasminogen activator inhibitor-1 (PAI-1) levels and the outcome of thrombolysis with streptokinase in patients with acute myocardial infarction
21. Increased levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction
22. PAI-1, obesity, insulin resistance and risk of cardiovascular events
23. The adipocyte and hemostatic balance in obesity. Studies of PAI-1
24. Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentration: A family study with part of the Stanislas Cohort
25. PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis. Relation to environmental and genetic determinants
26. Plasminogen activator inhibitor-1 (PAI-1) content in platelets from healthy individuals genotyped for the 4G/5G polymorphism in the PAI-1 gene
27. Fibrinolytic balance, the renin-angiotensin system and atherosclerotic disease
28. Circadian variations of onset of acute myocardial infarction and efficacy of thrombolytic therapy
29. Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke
30. Circadian variation of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction
31. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1)
32. The thrombolysis in myocardial infarction (TIMI) trial; Phase I findings
33. Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets
34. Reteplase (r-PA): A novel recombinant plasminogen activator
35. Randomized, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction: Trial to investigate equivalence
36. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction
37. Improved thrombolysis in acute myocardial infarction with front-loaded administaration of alteplase: Results of the rt-PAAPSAC patency study (TAPS)
38. Randomized comparison of coronary thrombolysis achieved with double bolus reteplase (r-PA) and front-loaded 'accelerated' alteplase (rt-PA) in patients with acute myocardial infarction
39. Clot-selective compared with non-selective fibrinolytic drugs: Deja vu - All over again
40. A comparison of reteplase with alteplase for acute myocardial infarction
41. Protein engineering of novel plasminogen activators with increased thrombolytic potency in rabbits relative to activase
42. Serial changes of plasminogen activator inhibitor activity in thrombolytic therapy for acute myocardial infarction. Comparison between thrombolytic therapies with mutant t-PA (lanoteplase/BMS-200980) and recombinant TPA (alteplase)
43. Evaluation of a weight-adjusted single bolus plasminogen activator in patients with myocardial infarction. A double-blind, randomized angiographic trial of lanoteplase versus alteplase
44. A variant of tissue plasminogen activator (t103N, N117Q, KHRR 296-299 AAAA) with a decreased plasma clearance rate is substantially more potent than Activase TM rt-PA in a rabbit thrombolysis model
45. A slow clearing, fibrin-specific PAI-1 resistant variant of t-PA (T103N, KHRR 296-299 AAAA)
46. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: Results of the TIMI 10B trial. Thrombolysis in myocardial infarction (TIMI) 10B investigators
47. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomised trial Assessment of the safety and efficacy of a new thrombolytic (ASSENT-2) investigators
48. Reduction of reinfarction and angina with use of low-molecular-weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction
49. Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after anterior myocardial infarction. The Fragmin in Acute Myocardial Infarction (FRAMI) study
50. Impact of hirudin versus heparin on mortality and (re)infarction in patients with acute coronary syndromes: A prospective meta-analysis of the GUSTO.IIb and TIMI 9b trials
51. Abciximab facilitates the rate and extent of thrombolysis. Results of the thrombolysis in myocardial infarction (TIMI) 14 trial